Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | IgA Vasculitis | Case report

IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report

Authors: Illeon Cho, Jwa-Kyung Kim, Sung Gyun Kim

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Following the strong recommendation for coronavirus disease 2019 (COVID‑19) vaccination, many patients with medical comorbidities are being immunized. However, the safety of vaccination in patients with autoimmune diseases has not been well established. We report a new case of biopsy-proven IgA vasculitis with nephritis presenting as a nephrotic syndrome after mRNA COVID-19 vaccination in a patient with a history of leukocytoclastic vasculitis.

Case presentation

A 76-year-old man with a history of cutaneous leukocytoclastic vasculitis presented with purpura in both lower limbs, followed by nephrotic syndrome after the second dose of BNT162b2 mRNA COVID-19 vaccination. Skin and renal biopsy revealed IgA vasculitis with nephritis. The patient’s past medical history of leukocytoclastic vasculitis and features of chronicity in renal pathology suggest an acute exacerbation of preexisting IgA vasculitis after COVID-19 vaccination. After the steroid and renin-angiotensin system inhibitor use, purpura and acute kidney injury recovered within a month. Subnephrotic proteinuria with microscopic hematuria remained upon follow-up.

Conclusion

Physicians should keep in mind the potential (re)activation of IgA vasculitis following mRNA COVID-19 vaccines. It is important to closely monitor COVID-19 vaccinated patients, particularly those with autoimmune diseases.
Literature
1.
go back to reference Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195–7.CrossRef Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195–7.CrossRef
2.
go back to reference Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T. Nature. 2020;586(7830):594–9.CrossRef Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T. Nature. 2020;586(7830):594–9.CrossRef
4.
go back to reference Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef
5.
go back to reference Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef
6.
go back to reference Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–9.CrossRef Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–9.CrossRef
7.
go back to reference Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a Nationwide Mass Vaccination setting. N Engl J Med. 2021;384(15):1412–23.CrossRef Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a Nationwide Mass Vaccination setting. N Engl J Med. 2021;384(15):1412–23.CrossRef
8.
go back to reference Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int. 2021;100(5):959–65.CrossRef Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int. 2021;100(5):959–65.CrossRef
9.
go back to reference Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021;6(12):2969–78.CrossRef Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021;6(12):2969–78.CrossRef
11.
go back to reference Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021;99(6):1487.CrossRef Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021;99(6):1487.CrossRef
12.
go back to reference Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021;100(1):238.CrossRef Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021;100(1):238.CrossRef
13.
go back to reference Perrin P, Bassand X, Benotmane I, Bouvier N. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int. 2021;100(2):466–8.CrossRef Perrin P, Bassand X, Benotmane I, Bouvier N. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int. 2021;100(2):466–8.CrossRef
14.
go back to reference Tan HZ, Tan RY, Choo JCJ, Lim CC, Tan CS, Loh AHL, et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int. 2021;100(2):469–71.CrossRef Tan HZ, Tan RY, Choo JCJ, Lim CC, Tan CS, Loh AHL, et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int. 2021;100(2):469–71.CrossRef
15.
go back to reference Kudose S, Friedmann P, Albajrami O, D’Agati VD. Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy. Kidney Int. 2021;100(2):468–9.CrossRef Kudose S, Friedmann P, Albajrami O, D’Agati VD. Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy. Kidney Int. 2021;100(2):468–9.CrossRef
16.
go back to reference Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int. 2021;100(2):474–6.CrossRef Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int. 2021;100(2):474–6.CrossRef
17.
go back to reference Hanna C, Herrera Hernandez LP, Bu L, Kizilbash S, Najera L, Rheault MN, et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int. 2021;100(3):705–6.CrossRef Hanna C, Herrera Hernandez LP, Bu L, Kizilbash S, Najera L, Rheault MN, et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int. 2021;100(3):705–6.CrossRef
18.
go back to reference Plasse R, Nee R, Gao S, Olson S. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination. Kidney Int. 2021;100(4):944–5.CrossRef Plasse R, Nee R, Gao S, Olson S. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination. Kidney Int. 2021;100(4):944–5.CrossRef
19.
go back to reference Park K, Miyake S, Tai C, Tseng M, Andeen NK, Kung VL. “A case of Gross Hematuria and IgA Nephropathy Flare-Up following SARS-CoV-2 Vaccination”. Kidney Int Rep. 2021;6(8):2246–7.CrossRef Park K, Miyake S, Tai C, Tseng M, Andeen NK, Kung VL. “A case of Gross Hematuria and IgA Nephropathy Flare-Up following SARS-CoV-2 Vaccination”. Kidney Int Rep. 2021;6(8):2246–7.CrossRef
20.
go back to reference Abramson M, Mon-Wei Yu S, Campbell KN, Chung M, Salem F. IgA Nephropathy after SARS-CoV-2 vaccination. Kidney Med. 2021;3(5):860–3.CrossRef Abramson M, Mon-Wei Yu S, Campbell KN, Chung M, Salem F. IgA Nephropathy after SARS-CoV-2 vaccination. Kidney Med. 2021;3(5):860–3.CrossRef
21.
go back to reference Horino T. IgA nephropathy flare-up following SARS-CoV-2 vaccination. QJM. 2021;114(10):735–6.CrossRef Horino T. IgA nephropathy flare-up following SARS-CoV-2 vaccination. QJM. 2021;114(10):735–6.CrossRef
22.
go back to reference Sugita K, Kaneko S, Hisada R, Harano M, Anno E, Hagiwara S, et al. Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review. CEN Case Rep. 2022;11(4):436–41.CrossRef Sugita K, Kaneko S, Hisada R, Harano M, Anno E, Hagiwara S, et al. Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review. CEN Case Rep. 2022;11(4):436–41.CrossRef
23.
go back to reference Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, et al. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;11(3):358–62.CrossRef Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, et al. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;11(3):358–62.CrossRef
24.
go back to reference Horino T, Sawamura D, Inotani S, Ishihara M, Komori M, Ichii O. Newly diagnosed IgA nephropathy with gross haematuria following COVID-19 vaccination. QJM. 2022;115(1):28–9.CrossRef Horino T, Sawamura D, Inotani S, Ishihara M, Komori M, Ichii O. Newly diagnosed IgA nephropathy with gross haematuria following COVID-19 vaccination. QJM. 2022;115(1):28–9.CrossRef
25.
go back to reference Park JS, Lee EY. Renal side effects of COVID-19 vaccines in patients with immunoglobulin A nephropathy. Kidney Res Clin Pract. 2022;41(1):124–7.CrossRef Park JS, Lee EY. Renal side effects of COVID-19 vaccines in patients with immunoglobulin A nephropathy. Kidney Res Clin Pract. 2022;41(1):124–7.CrossRef
26.
go back to reference Niel O, Florescu C. IgA nephropathy presenting as rapidly progressive glomerulonephritis following first dose of COVID-19 vaccine. Pediatr Nephrol. 2022;37(2):461–2.CrossRef Niel O, Florescu C. IgA nephropathy presenting as rapidly progressive glomerulonephritis following first dose of COVID-19 vaccine. Pediatr Nephrol. 2022;37(2):461–2.CrossRef
27.
go back to reference Abdel-Qader DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, Al Meslamani AZ, Elmusa RA. IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine. Vaccine. 2022;40(18):2528–30.CrossRef Abdel-Qader DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, Al Meslamani AZ, Elmusa RA. IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine. Vaccine. 2022;40(18):2528–30.CrossRef
28.
go back to reference Okada M, Kikuchi E, Nagasawa M, Oshiba A, Shimoda M. An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine. CEN Case Rep. 2022;11(3):376–9.CrossRef Okada M, Kikuchi E, Nagasawa M, Oshiba A, Shimoda M. An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine. CEN Case Rep. 2022;11(3):376–9.CrossRef
29.
go back to reference Fujita Y, Yoshida K, Ichikawa D, Shibagaki Y, Yazawa M. Abrupt worsening of occult IgA nephropathy after the first dose of SARS-CoV-2 vaccination. CEN Case Rep. 2022;11(3):302–8.CrossRef Fujita Y, Yoshida K, Ichikawa D, Shibagaki Y, Yazawa M. Abrupt worsening of occult IgA nephropathy after the first dose of SARS-CoV-2 vaccination. CEN Case Rep. 2022;11(3):302–8.CrossRef
30.
go back to reference Lo WK, Chan KW. Gross haematuria after mRNA COVID-19 vaccination in two patients with histological and clinical diagnosis of IgA nephropathy. Nephrol (Carlton). 2022;27(1):110–1.CrossRef Lo WK, Chan KW. Gross haematuria after mRNA COVID-19 vaccination in two patients with histological and clinical diagnosis of IgA nephropathy. Nephrol (Carlton). 2022;27(1):110–1.CrossRef
31.
go back to reference Leong LC, Hong WZ, Khatri P. Reactivation of minimal change disease and IgA nephropathy after COVID-19 vaccination. Clin Kidney J. 2022;15(3):569–70.CrossRef Leong LC, Hong WZ, Khatri P. Reactivation of minimal change disease and IgA nephropathy after COVID-19 vaccination. Clin Kidney J. 2022;15(3):569–70.CrossRef
32.
go back to reference Lim JH, Kim MS, Kim YJ, Han MH, Jung HY, Choi JY, et al. New-onset kidney diseases after COVID-19 vaccination: a case series. Vaccines (Basel). 2022;10(2):302.CrossRef Lim JH, Kim MS, Kim YJ, Han MH, Jung HY, Choi JY, et al. New-onset kidney diseases after COVID-19 vaccination: a case series. Vaccines (Basel). 2022;10(2):302.CrossRef
33.
go back to reference Srinivasan V, Geara AS, Han S, Hogan JJ, Coppock G. Need for symptom monitoring in IgA nephropathy patients post COVID-19 vaccination. Clin Nephrol. 2022;97(3):193–4.CrossRef Srinivasan V, Geara AS, Han S, Hogan JJ, Coppock G. Need for symptom monitoring in IgA nephropathy patients post COVID-19 vaccination. Clin Nephrol. 2022;97(3):193–4.CrossRef
34.
go back to reference Morisawa K, Honda M. Two patients presenting IgA nephropathy after COVID-19 vaccination during a follow-up for asymptomatic hematuria. Pediatr Nephrol. 2022;37(7):1695–6.CrossRef Morisawa K, Honda M. Two patients presenting IgA nephropathy after COVID-19 vaccination during a follow-up for asymptomatic hematuria. Pediatr Nephrol. 2022;37(7):1695–6.CrossRef
35.
go back to reference Nihei Y, Kishi M, Suzuki H, Koizumi A, Yoshida M, Hamaguchi S, et al. IgA Nephropathy with Gross Hematuria following COVID-19 mRNA vaccination. Intern Med. 2022;61(7):1033–7.CrossRef Nihei Y, Kishi M, Suzuki H, Koizumi A, Yoshida M, Hamaguchi S, et al. IgA Nephropathy with Gross Hematuria following COVID-19 mRNA vaccination. Intern Med. 2022;61(7):1033–7.CrossRef
36.
go back to reference Yokote S, Ueda H, Shimizu A, Okabe M, Yamamoto K, Tsuboi N, et al. IgA nephropathy with glomerular capillary IgA deposition following SARS-CoV-2 mRNA vaccination: a report of three cases. CEN Case Rep. 2022;11(4):499–505.CrossRef Yokote S, Ueda H, Shimizu A, Okabe M, Yamamoto K, Tsuboi N, et al. IgA nephropathy with glomerular capillary IgA deposition following SARS-CoV-2 mRNA vaccination: a report of three cases. CEN Case Rep. 2022;11(4):499–505.CrossRef
37.
go back to reference Uchiyama Y, Fukasawa H, Ishino Y, Nakagami D, Kaneko M, Yasuda H, et al. Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination. BMC Nephrol. 2022;23(1):216.CrossRef Uchiyama Y, Fukasawa H, Ishino Y, Nakagami D, Kaneko M, Yasuda H, et al. Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination. BMC Nephrol. 2022;23(1):216.CrossRef
38.
go back to reference Watanabe S, Zheng S, Rashidi A. IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report. BMC Nephrol. 2022;23(1):135.CrossRef Watanabe S, Zheng S, Rashidi A. IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report. BMC Nephrol. 2022;23(1):135.CrossRef
39.
go back to reference Udagawa T, Motoyoshi Y. Macroscopic hematuria in two children with IgA nephropathy remission following Pfizer COVID-19 vaccination. Pediatr Nephrol. 2022;37(7):1693–4.CrossRef Udagawa T, Motoyoshi Y. Macroscopic hematuria in two children with IgA nephropathy remission following Pfizer COVID-19 vaccination. Pediatr Nephrol. 2022;37(7):1693–4.CrossRef
40.
go back to reference Schaubschlager T, Rajora N, Diep S, Kirtek T, Cai Q, Hendricks AR, et al. De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: a report of six cases from a single center. Clin Nephrol. 2022;97(5):289–97.CrossRef Schaubschlager T, Rajora N, Diep S, Kirtek T, Cai Q, Hendricks AR, et al. De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: a report of six cases from a single center. Clin Nephrol. 2022;97(5):289–97.CrossRef
41.
go back to reference Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69(11):1934–8.CrossRef Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69(11):1934–8.CrossRef
42.
go back to reference Maritati F, Canzian A, Fenaroli P, Vaglio A. Adult-onset IgA vasculitis (Henoch-Schönlein): update on therapy. Presse Med. 2020;49(3):104035.CrossRef Maritati F, Canzian A, Fenaroli P, Vaglio A. Adult-onset IgA vasculitis (Henoch-Schönlein): update on therapy. Presse Med. 2020;49(3):104035.CrossRef
43.
go back to reference Group KDIGOKGDW. KDIGO 2021 Clinical Practice Guideline for the management of glomerular Diseases. Kidney Int. 2021;100(4S):1–276. Group KDIGOKGDW. KDIGO 2021 Clinical Practice Guideline for the management of glomerular Diseases. Kidney Int. 2021;100(4S):1–276.
44.
go back to reference Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480.CrossRef Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480.CrossRef
45.
go back to reference Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for Autoimmune Diseases. Front Immunol. 2020;11:617089.CrossRef Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for Autoimmune Diseases. Front Immunol. 2020;11:617089.CrossRef
46.
go back to reference Hastings MC, Rizk DV, Kiryluk K, Nelson R, Zahr RS, Novak J, et al. IgA vasculitis with nephritis: update of pathogenesis with clinical implications. Pediatr Nephrol. 2022;37(4):719–33.CrossRef Hastings MC, Rizk DV, Kiryluk K, Nelson R, Zahr RS, Novak J, et al. IgA vasculitis with nephritis: update of pathogenesis with clinical implications. Pediatr Nephrol. 2022;37(4):719–33.CrossRef
47.
go back to reference Suso AS, Mon C, Oñate Alonso I, Galindo Romo K, Juarez RC, Ramírez CL, et al. IgA Vasculitis with Nephritis (Henoch-Schönlein Purpura) in a COVID-19 patient. Kidney Int Rep. 2020;5(11):2074–8.CrossRef Suso AS, Mon C, Oñate Alonso I, Galindo Romo K, Juarez RC, Ramírez CL, et al. IgA Vasculitis with Nephritis (Henoch-Schönlein Purpura) in a COVID-19 patient. Kidney Int Rep. 2020;5(11):2074–8.CrossRef
48.
go back to reference Sandhu S, Chand S, Bhatnagar A, Dabas R, Bhat S, Kumar H, et al. Possible association between IgA vasculitis and COVID-19. Dermatol Ther. 2021;34(1):e14551.CrossRef Sandhu S, Chand S, Bhatnagar A, Dabas R, Bhat S, Kumar H, et al. Possible association between IgA vasculitis and COVID-19. Dermatol Ther. 2021;34(1):e14551.CrossRef
49.
go back to reference Barbetta L, Filocamo G, Passoni E, Boggio F, Folli C, Monzani V. Henoch-Schönlein purpura with renal and gastrointestinal involvement in course of COVID-19: a case report. Clin Exp Rheumatol. 2021;39(Suppl 129(2):191–2.CrossRef Barbetta L, Filocamo G, Passoni E, Boggio F, Folli C, Monzani V. Henoch-Schönlein purpura with renal and gastrointestinal involvement in course of COVID-19: a case report. Clin Exp Rheumatol. 2021;39(Suppl 129(2):191–2.CrossRef
50.
go back to reference AlGhoozi DA, AlKhayyat HM. A child with Henoch-Schonlein purpura secondary to a COVID-19 infection. BMJ Case Rep. 2021;14(1):e239910.CrossRef AlGhoozi DA, AlKhayyat HM. A child with Henoch-Schonlein purpura secondary to a COVID-19 infection. BMJ Case Rep. 2021;14(1):e239910.CrossRef
Metadata
Title
IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report
Authors
Illeon Cho
Jwa-Kyung Kim
Sung Gyun Kim
Publication date
01-12-2022

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue